Nuclear medicine imaging and therapy of neuroendocrine tumours.
Publication year
2006Source
Cancer Imaging, 6, (2006), pp. S178-84ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Nuclear Medicine
Journal title
Cancer Imaging
Volume
vol. 6
Page start
p. S178
Page end
p. 84
Subject
IGMD 1: Functional imaging; N4i 1: Pathogenesis and modulation of inflammation; NCMLS 2: Immune Regulation; ONCOL 3: Translational research; ONCOL 5: Aetiology, screening and detection; UMCN 1.1: Functional ImagingAbstract
Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.
This item appears in the following Collection(s)
- Academic publications [245398]
- Electronic publications [132942]
- Faculty of Medical Sciences [93205]
- Open Access publications [106465]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.